Abstract P205 Table 1 Crude admission rates, Poisson regression modelling of admissions, mortality and median ICU length of stay in people with Bronchiectasis and Chronic Obstructive Pulmonary Disease (COPD)

Bronchiectasis	Number of admissions	Person years	Crude admission rate per 100,000 person years (95% CI)	Crude admissions rate ratio (95% CI)	Number of ICU deaths (%)	Median length of stay on ICU [#] (IQR)
Year						
2009	74	97,457	75.9 (60.5–95.4)	1.00	20 (27.0)	3.0 (1.0–5.0)
2010	78	114,207	68.3 (54.7–85.3)	0.90 (0.65–1.24)	18 (23.1)	3.5 (1.4–6.4)
2011	108	128,659	83.9 (69.5–101.4)	1.11 (0.82–1.49)	22 (20.4)	2.1 (1.0–5.1)
2012	155	137,062	113.1 (96.6–132.7)	1.49 (1.13–1.96)	31 (20.0)	3.8 (1.1–7.3)
2013	121	136,877	88.4 (74.0–105.6)	1.16 (0.87–1.55)	35 (28.9)	2.9 (1.4–7.1)
*p for trend = 0.022						
COPD						
Year						
2009	3126	97,457	3204.6 (3094.2–3318.9)	1.00	642 (20.5)	3.2 (1.4–7.9)
2010	3675	114,207	3217.8 (3115.5–3223.6)	1.01 (0.96–1.05)	717 (19.5)	3.0 (1.4–6.7)
2011	3924	128,659	3049.9 (2956.0–3146.9)	0.95 (0.91–1.00)	718 (18.3)	2.9 (1.3–6.3)
2012	4377	137,062	3193.4 (3100.2–3289.5)	0.99 (0.95–1.04)	818 (18.7)	3.0 (1.4–6.4)
2013	4652	136,877	3398.7 (3302.4–3497.8)	1.06 (1.01–1.11)	837 (18.0)	3.1 (1.5–6.6)
*p for trend = 0.0003						

*p value for likelihood ratio test. [#]length of stay in days.

bronchiectasis and 19,754 (3.2%) from COPD. Bronchiectasis admissions increased from 74 in 2009 to 121 in 2013, equating to a crude annual increase of 8% (95% Confidence Interval [CI] 2 to 15%; $p = 0.01$) (see Table 1). The mean age increased from 56.6 (standard deviation [SD] 18) to 65.8 years (SD 15.2; $p = 0.042$) whilst ICU mortality did not change (27.0% vs 28.9%; $p = 0.83$). The unadjusted yearly increase in COPD admissions was 1% (95% CI: 0.3% to 2%; $p = 0.012$). The mean age in COPD patients remained static (67.5 years [SD 10.6] vs. 67.9 years [SD 10.6]; $p = 0.16$), but ICU mortality decreased (20.5% vs. 18.0%; $p = 0.005$). ICU mortality in people with bronchiectasis over 70 ($n = 219$) was higher compared to those under 70 (31.1% vs. 18.3%; $p < 0.001$) despite having similar mean APACHE II acute physiology scores.

Conclusion Bronchiectasis admissions to ICU are increasing, and ICU mortality for is higher bronchiectasis compared to COPD, particularly in individuals above 70 years of age.

P206 EXPERIENCE OF ESTABLISHING FUNDING FOR A HOME IV SERVICE FOR BRONCHIECTASIS

A Booth, A McCleary, RA Thomas. *York Hospitals NHS Trust, York, UK*

10.1136/thoraxjnl-2015-207770.342

Background The benefit of intravenous (IV) antibiotics in bronchiectasis has been established,¹ and IV antibiotics can be safely delivered in a domiciliary setting.² We report on the experience of obtaining funding through the CCG to establish a service delivering IV antibiotics safely and effectively to people with bronchiectasis at home.

Methods The model for home IV antibiotics involved a vascular surgeon placing a PICC line on day one under guided ultrasound, and an initial review by specialist nurse and physiotherapist. The specialist nurse administered the first dose. Education on line care, anaphylaxis and potential complications was provided. Drugs were delivered via a homecare company, Calea, and home IV doses were administered by specialist nurses from the homecare company. At the end of the course patients were reviewed by the specialist bronchiectasis nurse.

Results Negotiations with the CCG agreed funding for the service with 7.5 h of specialist nurse time and to meet the costs of the homecare company. Between July 2014 and July 2015 9 patients underwent 10 IV courses. A total of 132 days IV antibiotics were given, with 96 (73%) being given at home. This saved bed days, at an estimated saving of £26,400. Seventy seven home visits were conducted by the homecare company specialist nurses at a cost of £5625 and the homecare drug cost was £6134 (total £11,759 or £1,175 per course). Overall cost savings amounted to approximately £20,266 for the ten courses, or £2,026 per course. One patient had to return to hospital for replacement of their line due to mechanical phlebitis, but was still able to complete the entire course. Qualitative feedback is being sought via patient questionnaires, and has proved very positive.

Conclusion Administering IV antibiotics at home for people with bronchiectasis is safe, reduces inpatient bed days and is cost effective.

REFERENCES

- Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. *Eur Respir J*. 2009;**33**:312–8
- Bedi P, Sidhu MK, Donaldson LS, et al. A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis. *NPJ Prim Care Respir Med*. 2014;**24**:14090

P207 THORACIC INVOLVEMENT IN IGG4-RELATED DISEASE

¹RM Anstey, ¹JP Corcoran, ²EL Culver, ¹A Talwar, ¹RJ Hallifax, ¹I Psallidas, ²TN Cargill, ²CD Manganis, ²E Barnes, ¹NM Rahman. ¹Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK; ²Translational Gastroenterology Unit, Oxford University Hospitals NHS Trust, Oxford, UK

10.1136/thoraxjnl-2015-207770.343

Background and objectives IgG4-related disease (IgG4-RD) is a multi-system fibro-inflammatory disorder originally described in association with autoimmune pancreatitis (AIP), usually but not always in the context of elevated serum IgG4 levels. Thoracic manifestations of IgG4-RD include mediastinal lymphadenopathy, lung nodules or masses, interstitial lung disease, bronchiectasis and pleural disease.